Adding checkpoint inhibition to anti-HER2 breast cancer therapy brings no benefit
Adding an immune checkpoint inhibitor to anti-HER2 treatment in breast cancer does not improve pathological complete response (pCR), according to the primary analysis of the IMpassion050 trial presented today during the ESMO ...
Jun 17, 2021
0
1